What you should know:
1. Ironwood’s irritable bowel syndrome with constipation and chronic idiopathic constipation drug linaclotide is a commercial success with $264 million in collaboration revenue and $70 million in API sales in 2018.
2. Ironwood is hoping to build on that success with its developmental drug candidates. Ironwood is developing a persistent gastroesophageal reflux disease treatment and a pain treatment for irritable bowel syndrome with diarrhea sufferers.
3. Ironwood will continue to trade under its current symbol. Cyclerion began trading on the Nasdaq Stock Market on April 2, under the CYCN symbol.
4. Ironwood CEO Mark Mallon said, “Today marks the beginning of a new chapter for Ironwood, one that combines a strong drug development and commercial foundation with a sharpened focus on our core objective — creating medicines that make a difference for people living with GI diseases.”
More articles on gastroenterology:
Brookside ENT and Hearing Center closes after hack deletes all files — 7 insights
Pharmacists to join outpatient care teams in new arrangement — 4 insights
5 must-read articles for the ASC industry this week: March 22 – 28
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.